Ridgeback Capital is an actively managed private investment firm founded by Dr. Wayne Holman in 2006, specializing in both securities trading and long-term private investments in the life sciences and biopharma sectors. The firm provides patient capital to private and public healthcare companies developing life-saving and life-changing therapies.
68% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $109.4M (across 20 rounds with reported amounts).
Portfolio
18
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
CB
Craig Burns
Managing Director
LS
Leo Sternlicht
Managing Director
MM
Matt Mezvinsky
Managing Director
WH
Wayne Holman
Founder & CEO
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
22 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Hinge Bio | Series A | $30M | Jan 2025 |
 Freenome | Series D | $300M | Dec 2021 |
 Quell Therapeutics | Series B | $156M | Nov 2021 |
 Quell | Unknown | $156M | Nov 2021 |
 Arbor Biotechnologies | Series B | $215M | Nov 2021 |
 Turnstone Biologics | Series D | $80M | Jul 2021 |
 Reverie | Series A | $25M | Feb 2021 |
 Reverie Labs | Series A | $25M | Feb 2021 |
| Quell Therapeutics | Series B | $156M | Jan 2021 |
 Acepodia | Series B | $47M | Jan 2021 |
 Arbor Biotechnologies | Series B | $215M | Jan 2021 |
 TwinStrand Biosciences | Series B | $50M | Jan 2021 |
 4DMT | Series C | $75M | Jun 2020 |
| TwinStrand Biosciences | Series A | — | Jan 2020 |
| 4DMT | Series B | $90M | Sep 2018 |
 Adaptimmune | Series A | $104M | Jan 2014 |
 Precision BioSciences | Series B | $110M | — |
 Caribou | Series C | $115M | — |
 Bellicum Pharmaceuticals | Series C | $55M | — |
| TTurnstone | Series D | — | — |
| Acepodia | Series C | $109M | — |
 4D Molecular Therapeutics | Series C | $75M | — |
Top Co-Investors
ArrowMark Partners7 shared
Tekla Capital Management6 shared
Perceptive Advisors5 shared
Surveyor Capital4 shared
F-Prime Capital4 shared
Eventide Asset Management3 shared
T. Rowe Price3 shared
S323 shared
Logos Capital3 shared
RA Capital Management3 shared
Alexandria Venture Investments3 shared
PFM Health Sciences3 shared
SV Health Investors3 shared
Jeito Capital3 shared
British Patient Capital3 shared
OrbiMed3 shared
Berkeley Catalyst Fund3 shared
Viking Global Investors3 shared
Pfizer Ventures3 shared
Y Combinator3 shared
Last updated: 20 October 2026